TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Optimization of Novel DCE-MRI Imaging Sequences for Cancer Therapy Monitoring

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~All subjects are eligible except for the following special cases:~Exclusion Criteria:~* Female subjects who are or may be pregnant will NOT be eligible.~* The minimum age for all subjects is 18 years old. No subjects under the age of 18 shall be considered.~* If subject has received an imaging contrast agent of any kind within the past 7 days, they shall not be included in the study.~* Subjects for whom MRI is contraindicated as set forth by the City of Hope Department of Radiology. These include:~  * electrical implants such as cardiac pacemakers or perfusion pumps~ * ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants~ * ferromagnetic objects such as jewelry or metal clips in clothing~ * pre-existing medical conditions, including a likelihood of developing seizures or anxiety disorders such as claustrophobia, panic attacks or any psychiatric disorder~ * any greater than normal potential for cardiac arrest~ * any subject with known kidney insufficiency function as evidenced by an abnormal serum creatinine (normal = 0.6 - 1.5 mg/dL) from a blood test performed on the subject within the past 6 months of the study date.~ * Any subject with abnormal creatinine clearance (normal = 100-130 ml/min/1.73m2), as measured by a direct test or from plasma creatinine (14) levels shall be excluded.~* Normal subjects with a history of severe claustrophobia will not be eligible.~* For ease of recruiting and study management purposes, only subjects who can give consent in English shall be eligible for this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: t

Study Arms:
- DCE-MRI (dynamic contrast-enhanced MRI) (Type: None): Patients undergo DCE-MRI over approximately 30-60 minutes consisting of an anatomical scout image to localize the region of interest, a set of pre-injection scans to calibrate the dynamic image set, a dynamic image set during which contrast agent will be injected, and a set of post-injection scans to calibrate the DCE-MRI database.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Screening for COPD in Primary Care: a Synergistic Approach - Dentists - Pharmacists -Physiotherapists - Nurses - Physicians

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age over 40 years,~* Smoking greater than 10 packs / year, active.~* No previous diagnosis of COPD~* Signature of informed consent~Exclusion Criteria:~* Patients under 40 years of age~* Previous of COPD diagnosis~* Refusing to participate

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- COPD screening (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Parental Presence During Fracture Reduction in Children at the Emergency Department; A Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria for patients:~* Patients aged 8 to 18 years old.~* Patients requiring fracture reduction under conscious sedation by emergency department attending physician.~* Patients able to understand basic spoken English or French.~Inclusion criteria for parents:~* Parents able to understand basic spoken English or French.~Exclusion criteria for patients:~* Patients with moderate to severe mental retardation~* Patients with altered mental status or intoxication~* Patients with hemodynamic instability or several traumatic injuries (other than fractures) - these patients require several treatments and may not have time to complete our study.~Exclusion criteria for parents:~* Parents presenting unacceptable behaviors for family presence~  * Uncooperative~ * Physically aggressive, combative~ * Threatening and argumentative~ * Unstable emotionally or cannot be calmed~ * Intoxicated or altered mental status~ * Suspicion of child abuse~ * Suspected perpetrator of violent crime~* Parents with moderate to severe mental retardation.~* Pregnant parent

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Parental presence (Type: EXPERIMENTAL): Patients in the study group will be accompanied by one of their parents for the whole procedure. Before this, a short explanation of the procedure, the patient's expected behavior during the procedure and what roles parents should play will be given to the parent by the research assistant. Parents will be seated close to the patient's head and will wear radiology proof gowns. If deemed necessary by the attending physician or if their behavior becomes unacceptable, parents can be asked to leave the procedure room at any given time. Parents will be allowed to leave the procedure room if they wish to at any time during the procedure.
- Control (Type: ACTIVE_COMPARATOR): One parent will stay with their child until he is in the procedure room and conscious sedation has begun. He will then be asked to leave the room and wait in an adjoining waiting room. The attending physician will invite the parent back in the room once the reduction is complete and the cast is done.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Carcinoid syndrome:~Participants must have histopathologically confirmed neuroendocrine tumor with 4 or more bowel movements per day on standard anti-diarrheal regimen (which includes somatostatin analogs and/or Telotristat Ethyl). Additionally, a plasma 5-HIAA, or a urine 24-hour 5-HIAA or plasma secretory hormone levels (VIP, gastrin) above the upper limit of normal per reference lab. Patients may be grouped into this cohort based on a previous plasma 5-HIAA level though the final cohort determination will be made based upon the 5-HIAA level drawn during screening.~Non-Carcinoid Syndrome:~Participants who have histopathologically confirmed neuroendocrine tumor and have 4 or more bowel movements per day on standard anti-diarrheal regimen (which may or may not include somatostatin analogs), but do not have elevated results for one of the following: plasma 5-HIAA, or 24-hour urine 5-HIAA or other plasma secretory hormone levels (VIP, gastrin) above the upper limit of normal per reference lab. Patients may be grouped into this cohort based on a previous plasma 5-HIAA level though the final cohort determination will be made based upon the 5-HIAA level drawn during screening~* ECOG performance status ≤ 2 (Karnofsky ≥60%)~* Ability to tolerate thin liquids by mouth at the time of enrollment.~* Ability to understand and the willingness to sign a written informed consent document.~* Subject who are willing to take enterade® as instructed will be eligible.~Exclusion Criteria:~* Known allergy to Stevia.~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active~* Clostridium difficile infection or history of Clostridium difficile infection.~* Participants with a history of inflammatory bowel disease, irritable bowel syndrome, bariatric surgery and/or Celiac disease.~* Participants with psychiatric illness/social situations that would limit compliance with study requirements.~* Patients who have had enterade® within the past 3 months.~* Pregnant or breastfeeding women. The safety of enterade® has not been validated in this patient population.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enterade (Type: EXPERIMENTAL): Carcinoid Syndrome: Participants will drink a bottle of Enterade two time per day for 4 weeks.
- Experimental (Type: EXPERIMENTAL): Non-Carcinoid Syndrome: Participants will drink a bottle of Enterade two time per day for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: 13C-Spirulina Nitrogen Content GEBT Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females, 18-85 years old at time of signing consent form~* Ability to eat test meal and provide breath samples~Exclusion Criteria:~* History or physical exam suggestive of systemic disease such as diabetes mellitus or pathophysiologic disorders such as renal failure, chronic heart disease, chronic respiratory disease, liver disease or malabsorption syndrome~* Symptoms consistent with delayed gastric emptying~* History of abdominal surgery except appendectomy~* Use of any medications that may alter gastric motility within two days of the study~* Use of narcotics or anticholinergics within two days of the study~* Females on hormone replacement therapy other than birth control medications~* Receipt of an investigational drug within 4 weeks of the study~* Pregnancy~* Intolerance or allergy to any component of Gastric Emptying Breath Test meal~* History of neurologic or psychiatric disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Low Nitrogen GEBT test meal (Type: EXPERIMENTAL): GEBT test meal containing low %N content (below 7%)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: StrataGraft® Skin Tissue as an Alternative to Autografting Full-thickness Complex Skin Defects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women aged 18-65 years, inclusive~2. Written informed consent~3. Sufficient healthy skin identified and reserved as a donor site in the event that the StrataGraft treatment site requires autografting~4. Complex skin defects of up to 49% Total Body Surface Area (TBSA) requiring excision and autografting~   * Total skin defect may consist of more than one wound area~5. Full-thickness complex skin defects requiring excision and autografting~6. Study treatment sites on the torso and limbs may be up to 200 cm2 in cohort 1 and 400 cm2 in cohort 2~7. For thermal burns only, first excision and grafting of treatment sites~Exclusion Criteria:~1. Pregnant women and prisoners~2. Subjects receiving systemic immunosuppressive therapy~3. Subjects with a known history of malignancy~4. Preadmission insulin-dependent diabetic subjects~5. Subjects with concurrent conditions that in the opinion of the investigator may compromise subject safety or study objectives~6. Expected survival of less than three months~7. Participation in the treatment group of an interventional study within the 90 days prior to enrollment~8. Chronic wounds~9. The face, head, neck, hands, feet, buttocks, perineum, and area over joints~10. Treatment sites with exposed tendon or bony prominences~11. Chemical and electrical burns~12. Treatment sites adjacent to unexcised eschar~13. Clinical suspicion of infection at the anticipated treatment sites

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- StrataGraft skin tissue (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Norwegian Tenecteplase Stroke Trial 2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
General inclusion criteria~* 18 years or older~* Ischaemic stroke with clinical symptoms corresponding to National Institutes of Health Stroke Scale Score (NIHSS) of \>5. All stroke sub-types and vascular distributions are eligible. A visible arterial occlusion is not required for inclusion.~* Treatment \<4½ hours after stroke onset or after awakening with symptoms.~* Informed consent by patient or by patient's family~Specific sub-set inclusion criteria~* Wake-Up Stroke: FLAIR-DWI mismatch on MRI as judged by the (neuro-) radiologist or neurologist.~* Thrombectomy: Occlusion of intracerebral artery technically accessible for endovascular embolectomy as defined by local treatment protocols.~Exclusion criteria~* Prestroke modified rankin scale of ≥3~* Large areas of hypodense ischaemic changes on baseline CT;~* Patients with systolic blood pressure \>185 mm Hg or diastolic blood pressure \>110 mm Hg in spite of acute antihypertensive treatment;~* Pregnant women (are treated with alteplase);~* Women with possible pregnancy (are treated with alteplase)~* Beast feeding women, if a 24 hours stop of feeding is not feasible.~* Clinical presentation suggesting subarachnoid haemorrhage even if baseline CT is normal;~* Known bleeding diathesis; use of oral anticoagulants with no antidot, INR ≥1,4; heparin \<48 hours and increased APTT; low molecular weight heparin(oid) \<24 hours; another investigational drug \<14 days;~* Patients with arterial puncture at a noncompressible site or lumbar puncture \<7 days; major surgery or serious trauma \<14 days; gastrointestinal or urinary tract hemorrhage \<14 days; clinical stroke \<2 months; history of intracranial haemorrhage; CNS neurosurgery \<2 months; serious head trauma \<2 months; pericarditis; sepsis; any serious medical illness likely to interact with treatment; confounding pre-existent neurological or psychiatric disease; unlikely to complete follow-up;~* Any condition that, in the opinion of the investigator, puts a patient at risk if treated with thrombolysis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tenecteplase (Type: ACTIVE_COMPARATOR): Tenecteplase
- Alteplase (Type: ACTIVE_COMPARATOR): Alteplase

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with mesothelioma~* Previously treated with only one course of chemotherapy for mesothelioma~* No previous treatment with vinorelbine~* No serious heart problems within the last 3 months~Exclusion Criteria:~* Serious abnormal laboratory values~* Severe or uncontrolled disease or condition as judged by the Investigator~* Pregnant or breast-feeding women~* Other cancers within the last 5 years~* Major surgery or radiation therapy within 4 weeks prior to starting study therapy~* Receipt of any investigational agents within 30 days prior to commencing study treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Vinorelbine
- 2 (Type: EXPERIMENTAL): Vandetanib

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Health-related Quality of Life in Patients at Nordic Clinic

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All Swedish speaking patients (\>/= 18 years) visiting the clinic will be asked to participate in the study by clinic personnel when they are visiting the clinic. All patients at the clinic are able to provide informed consent and to fill out online forms.~Exclusion Criteria:~* \<18 years, non-Swedish speaking

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectivity of Postpartum Dexamethasone for Women With Class I HELLP Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Postpartum women with Class I HELLP syndrome~Exclusion Criteria:~* Chronic users of corticosteroids~* Patients with chronic conditions affecting the laboratory parameters involved in the HELLP syndrome~* Women who had received antenatal corticosteroids to treat HELLP syndrome were excluded

- Gender: FEMALE
- Minimum Age: 13 Years
- Maximum Age: 49 Years
- Healthy Volunteers: f

Study Arms:
- saline solution (Type: PLACEBO_COMPARATOR): Placebo (saline solution), 2 mL, intravenous, every 12 hours, for 48 hours
- Dexamethasone (Type: ACTIVE_COMPARATOR): Dexamethasone, 10mg (2mL), intravenous, every 12 hours, for 48 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Preconception Treatment of an Asymptomatic Bacterial Infection in an Infertility Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women who are actively trying to conceive via intrauterine insemination or in vitro fertilization~Exclusion Criteria:~* Current use of an oral or vaginal antibiotic.~* History of allergy or adverse reaction to metronidazole.~* Prior enrollment in study (patients returning for repeat cycle may not be re-enrolled).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Metronidazole (Type: ACTIVE_COMPARATOR): Patients randomized to the metronidazole arm will receive metronidazole 500mg orally twice daily for seven days.
- Placebo (Type: PLACEBO_COMPARATOR): Patients randomized to the placebo arm will receive placebo orally twice daily for seven days(control arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Early Response Evaluation in NSCLC Patients Treated With Immunotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* willing and able to provide written informed consent for the study.~* ≥ 18 years of age on day of signing informed consent.~* confirmed diagnosis of NSCLC.~* Histological tumor biopsy for PD-L1 IHC assessment (DAKO assay) available.~* Ipsilateral hilar or mediastinal lymph node with a short axis diameter ≥1 cm.~* Eligible and planned to receive nivolumab according to EMA label and national guidelines.~* Measurable disease according to RECIST v1.1.~* WHO performance status of 0-2.~Exclusion Criteria:~* Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to baseline PET-scan.~* Has an active infection or had an active infection within 2 weeks prior to baseline PET-scan.~* Has a known history of hypersensitivity to contrast material.~* Isolated distant relapse after curative intent treatment for stage I-III NSCLC.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab (Type: OTHER): Nivolumab treatment according to label: 3 mg/kg nivolumab IV Q2W, 240mg Q2W or 480mg Q4W as an IV infusion until disease progression or unacceptable toxicity.~FDG PET-CT will be performed at baseline and between 7 and 14 days after treatment initiation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues